US Edition
Unicycive Therapeutics (UNCY) - Actions Taken To Address Issues That Caused The CRL - Channelchek
Summary by channelchek.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Unicycive Therapeutics (UNCY) - Actions Taken To Address Issues That Caused The CRL - Channelchek
Friday, August 15, 2025 Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc. Refer to the full report for the price target, fundamental analysis, and rating. Actions Taken To Correct Manufacturing Findings. Unicycive reported a 2Q25 loss of $6.4 million or $(0.52) per share, with cash on June 30, 2025 of $22.3 million. Based on our current estimates, we believe this is sufficient to fund oper…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
